新型冠状病毒灭活疫苗接种者免疫效果的真实世界研究

A real-world study of the immunogenicity of inactivated SARS-CoV-2 vaccine

目的 研究完成3剂次新型冠状病毒灭活疫苗(简称新冠灭活疫苗)接种者的免疫效果及其相关影响因素。方法 选择2020年12月至2021年10月在南昌市第九医院完成3剂次新冠灭活疫苗接种者,于接种第1剂后3周,第2剂后4周、16周、32周,和第3剂后4周,分别抽取静脉血检测新型冠状病毒中和抗体、IgG和IgM抗体。结果 共纳入参与者874例,男316例,女558例。第1剂后3周,第2剂后4周、16周、32周,第3剂后4周中和抗体阳性率分别为26.2%、86.6%、74.2%、78.2%、98.1%;IgG抗体阳性率分别为25.1%、93.2%、59.3%、45.7%、96.8%。中和抗体定量及IgG抗体定量在第2剂后4周、16周、32周及第3剂后4周均明显高于第1剂后3周(P<0.0001);第2剂后16周、32周均明显低于第2剂后4周(P <0.0001);第3剂后4周均明显高于第1剂后4周(P <0.0001)。结论 接种2剂新冠灭活疫苗可以产生较多数量的中和抗体和IgG抗体以发挥免疫效果,增加第3剂加强针后可以明显升高二者峰值。

Objective To study the immunogenicity and related factors of the 3 doses inactivated SARS-CoV-2 vaccine.Method People who received 3 doses of inactivated SARS-CoV-2 vaccine in Nanchang Ninth Hospital from December 2020 to October 2021 were selected,At 3 weeks after the first dose,4 weeks,16 weeks and 32 weeks after the second dose,and 4 weeks after the third dose,the blood neutralizing antibody,IgG and IgM antibody were detected respectively.Result A total of 874 participants were enrolled,including 316 males and 558 females.The positive rates of neutralizing antibody were 26.2%,86.6%,74.2%,78.2%and 98.1%respectively at 3 weeks after the first dose,4 weeks,16 weeks,32 weeks after the second dose and 4 weeks after the third dose;The positive rates of IgG antibody were 25.1%,93.2%,59.3%,45.7%and 96.8%respectively.The quantitation of neutralizing antibody and IgG antibody at 4,16,32 weeks after the second dose and 4 weeks after the third dose were significantly higher than those at 3 weeks after the first dose(P<0.0001);16,32 weeks after the second dose were significantly lower than 4 weeks after the second dose(P<0.0001);4 weeks after the third dose were significantly higher than 4 weeks after the second dose(P<0.0001).Conclusion Two doses of the inactivated SARS-CoV-2 vaccine can produce a large number of neutralizing and IgG antibodies to play the immune effect,and the addition of the third dose of booster can significantly increase the peak value of both.